Empagliflozin’s Cardiorenal Benefits Appear to Persist
A follow-up of a randomized clinical trial found that positive effects of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, were seen up to a year after patients with chronic kidney disease stopped treatment.